It has previously been shown that differences in TP53 mutation, as well as p53 protein expression, between breast cancer subtypes may confer variability in clinical behavior within these subtypes.29,31,32 However, to the best of our knowledge, the epidemiological relevance of p53 protein expression in molecular subtypes of breast cancer is yet to be evaluated in any previous study. This evidence concerns the gene TP53 and breast carcinoma.